


Form PTO-1595 (Rev. 09/04)
OMB No. 0651-0027 (exp. 6/30/2005)

U.S. Department of COMMERCE
United States Patent and Trademark Office

RECORDATION FORM COVER SHEET PATENTS ONLY	
HARR0020-102 (P020236US)	
To the Director of the U.S. Patents and Trademark Office: Please record the attached documents or the new address(es) below.	
<div>1. Name of conveying party(ies)/Execution Date(s): <div>Cobra Therapeutics LimitedMay 15, 2002; First AssignorDate of Execution</div> <div>Second AssignorDate of Execution</div> <div>Third AssignorDate of Execution</div> <div>Fourth AssignorDate of Execution</div> <div>Fifth AssignorDate of Execution</div> <div>Sixth AssignorDate of Execution</div> <div>Additional name of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</div></div>	<div>2. Name and address of receiving party(ies): Name: M.L. Laboratories PLC Street Address: 17 Hanover Square, 5th Floor City: London W1S 1HU Country: England Additional Name(s) & address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</div> <div>3. Nature of conveyance: <div><input type="checkbox"/> Assignment<input type="checkbox"/> Merger</div><div><input type="checkbox"/> Security Agreement<input type="checkbox"/> License Agreement</div><div><input type="checkbox"/> Change of Name<input checked="" type="checkbox"/> Other: Assent Agreement</div><div><input type="checkbox"/> Government Interest Assignment</div><div><input type="checkbox"/> Executive Order 9424, Confirmatory License</div></div>
<div>4. Application number(s) or patent number(s): <input type="checkbox"/> This document is being filed together with a new application. <div>A. Patent Application No.(s): B. Patent No.(s): 5,736,359; Issue Date: 04/07/1998</div> <div>Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No</div></div>	
<div>5. Name and address of party to whom correspondence concerning this document should be mailed: Name: Doreen Yatko Trujillo COZEN O'CONNOR, P.C. 1900 Market Street, 6th Floor Philadelphia, Pennsylvania 19103-3508 215.665.5593 – Direct Line 215.701.2005 – Direct Facsimile dtrujillo@cozen.com – Email Address</div>	<div>6. Total number of applications and patents involved: One</div> <div>7. Total fee (37 CFR 1.21(h) & 3.41)\$ 40.00 <div><input type="checkbox"/> Authorized to be charged by credit card</div><div><input checked="" type="checkbox"/> Authorized to be charged to deposit account number 50-1275</div><div><input type="checkbox"/> Enclosed</div><div><input type="checkbox"/> None required (government interest not affecting title)</div></div> <div>8. Payment Information a. Credit Card Last 4 Numbers _____ Expiration Date _____ b. Deposit Account Number 50-1275 Authorized User Name, Doreen Yatko Trujillo, Reg. 35,719</div>
<div>9. Signature: <div>Doreen Yatko Trujillo/Reg. No. 35,719 Name of Person Signing/ Reg. No.</div><div> SignatureDate</div><div>Total number of pages including cover sheet, attachments, and documents: Two</div></div>	

Documents to be recorded (including cover sheet) should be faxed to (703) 305-5995, or mailed to:
Mail Stop Assignment Recordation Services
Director of the United States Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

CH \$40.00 501275 5736359



Cobra Therapeutics

13th May 2002

Dr Edwina Wright (Technology Transfer Group)
Medical Research Council
20 Park Crescent
London
W1N 4AL

Dear Dr. Wright,

Agreement between you and Cobra Therapeutics Limited ("the Company") dated 11th June 2001 ("the Agreement")


It was announced on 29 April that the Company is involved in restructuring which will involve its R & D business being separated from its contract manufacturing business. The R & D activities, along with the staff involved in that business, will be transferred to ML Laboratories PLC ("ML"), the Company's parent company, following which ML will sell the Company (which will at that stage retain only its contract manufacturing business) to Buyers Guide PLC and ML. Both businesses will continue to work together in the future and indeed for the foreseeable future the Company will remain a subsidiary of ML. However, since the Agreement, and the rights subject to it, are more closely associated with the R&D Business ML and Cobra have agreed that the Agreement and the rights granted under it should be transferred to ML.

As you know, your consent is required for Cobra to assign the Agreement to ML, and we should be grateful if you would confirm your consent by signing below and returning one copy of the letter to me.

If you have any questions, please do not hesitate to contact me on 01782 714181. In the future, all enquiries should be addressed to the Director of Business Development at ML Laboratories, Stephenson Building, Science Park, Keele ST5 5SP, UK..

I should like to take this opportunity to thank you on behalf of Cobra for the support you have given it in the past. On behalf of ML, we look forward to working with you in the future and to build upon the relationship developed with Cobra.

Yours faithfully


John Wynne
Director, Business Development

I agree to the assignment of the Agreement to ML Laboratories

Signed...
For and on behalf of Medical Research Council

Martin R Wood PhD
Director, Licensing and Agreements
Medical Research Council Technology

Date: 15 May 2002


R. J. LOOSLEY
Notary Public
17 Hanover Square
LONDON
W1S 1HU
+44 020 7917 8500
rogerloosley@stringersaul.co.uk

Cobra Therapeutics Limited, Stephenson Building, Keele University Science Park, Keele, Staffordshire, ST5 5SP
United Kingdom, Tel: +44 (0)1782 714181 Fax: +44 (0)1782 714167/8
(Registered in England No. 2710654)

PATENT